Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies

Patients receiving anti-CD20 antibodies showed limited efficacy of a booster dose of BNT162b2. Patients with lymphomas combine such immunotherapies with cytotoxic chemotherapies that could result in an even greater alteration of the immune response to vaccination. We report here the impact of a thir...

Descripción completa

Detalles Bibliográficos
Autores principales: Gressens, Simon B., Wiedemann, Aurélie, Déchenaud, Marie, Dupuis, Jehan, Gallien, Sébastien, Melica, Giovanna, Haioun, Corinne, Lemonnier, François, Levy, Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884622/
https://www.ncbi.nlm.nih.gov/pubmed/36737320
http://dx.doi.org/10.1016/j.vaccine.2023.01.064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884622/
https://www.ncbi.nlm.nih.gov/pubmed/36737320
http://dx.doi.org/10.1016/j.vaccine.2023.01.064

Ejemplares similares